Hence, according to molecular signaling, nobiletin inhibits tumor progression by inhibiting the EGFR/JAK2/STAT3 pathway and PD-L1 expression in NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.